Three years after Apple Inc. (NASDAQ:AAPL) retail chief took over as CEO of J.C. Penney Co. Inc. (NYSE: JCP) and set a course that nearly ruined the company, the century-old retailer is back. Under CEO Myron E. (Mike) Ullman III, who Johnson replaced, J.C. Penney showed that its prospects to remain a major retailer have returned. Ullman was brought back when it was clear that J.C. Penney’s prospects had turned so bleak that some financial analysts believed it would go bankrupt. J.C. Penney Company, Inc. (NYSE:JCP) net profit margin is -11.70% and weekly performance is -2.11%. On last trading day company shares ended up $8.37. Analysts mean target price for the company is $7.75. J.C. Penney Company, Inc. (NYSE:JCP) distance from 50-day simple moving average (SMA50) is -1.52%.
ExOne (NASDAQ:XONE) was downgraded by equities researchers at Stephens from an “overweight” rating to an “equal weight” rating in a research report issued on Friday,TheFlyOnTheWall.com reports. ExOne Co (NASDAQ:XONE) shares fell -17.29% in last trading session and ended the day on $25.50. Gross Margin is 39.50% and its return on assets is -5.10%. ExOne Co (NASDAQ:XONE) quarterly performance is -42.83%.
Chemical Financial Corporation (NASDAQ:CHFC) the holding company for Chemical Bank, and Northwestern Bancorp, Inc. (“Northwestern”), the holding company for Northwestern Bank, today announced that the shareholders of Northwestern have approved the Agreement and Plan of Merger, dated March 10, 2014, pursuant to which Chemical will acquire all of the outstanding shares of Northwestern’s common stock in an all cash transaction valued at $120 million. Chemical Financial Corporation (NASDAQ:CHFC) shares moved down -0.72% in last trading session and was closed at $27.41, while trading in range of $26.99- $27.65. Chemical Financial Corporation (NASDAQ:CHFC) year to date (YTD) performance is -12.79%.
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has two reasons driving its shares to a record high level of nearly 30% today. Firstly, the company has signed an agreement to acquire Treximet’s U.S. rights from GlaxoSmithKline plc. Secondly, the company has forecasted its fiscal year 2015 guidance above analysts’ estimates. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) ended the last trading day at $6.43. Company weekly volatility is calculated as 15.39% and price to cash ratio as 15.56. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) showed a positive weekly performance of 48.16%.